ULTRAGENYX PHARMACEUTICAL INC. Payments to Acquire Intangible Assets
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Payments to Acquire Intangible Assets of $5.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireIntangibleAssets · last filed 2026-08-05
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire intangible assets for the quarter ending 2026-06-30 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire intangible assets for the quarter ending 2026-03-31 was $5.00M, a 66.67% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire intangible assets for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire intangible assets for the quarter ending 2025-09-30 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire intangible assets for fiscal 2025 was $15.00M, a 15.38% increase from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire intangible assets for fiscal 2024 was $13.00M, a 333.33% increase from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire intangible assets for fiscal 2023 was $3.00M, a 90.00% decline from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire intangible assets for fiscal 2022 was $30.00M.
| Period end | Payments to Acquire Intangible Assets 3 month | Payments to Acquire Intangible Assets 6 month | Payments to Acquire Intangible Assets 9 month | Payments to Acquire Intangible Assets 12 month | Payments to Acquire Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $5.00M 10-Q · filed 2026-08-05 | $5.00M derived: sum of 3 quarters · filed 2026-08-05 | $5.00M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $5.00M 10-Q · filed 2026-05-06 | $5.00M derived: sum of 2 quarters · filed 2026-05-06 | $5.00M derived: sum of 3 quarters · filed 2026-05-06 | $5.00M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $0.00 derived: sum of 2 quarters · filed 2026-02-18 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $15.00M 10-K · filed 2026-02-18 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2026-08-05 | $15.00M 10-Q · filed 2025-11-05 | $15.50M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $15.00M 10-Q · filed 2026-08-05 | $15.50M derived: sum of 3 quarters · filed 2026-08-05 | $15.50M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $15.00M 10-Q · filed 2026-05-06 | $15.50M derived: sum of 2 quarters · filed 2026-05-06 | $15.50M derived: sum of 3 quarters · filed 2026-05-06 | $18.00M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $500.00K derived: sum of 2 quarters · filed 2026-02-18 | $3.00M derived: sum of 3 quarters · filed 2026-02-18 | $13.00M 10-K · filed 2026-02-18 | $12.50M 10-K · filed 2025-02-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.50M derived: sum of 2 quarters · filed 2025-11-05 | $12.50M 10-Q · filed 2025-11-05 | $13.00M derived: sum of 4 quarters · filed 2026-02-18 | |
| 2024-06-30 | $2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $12.50M 10-Q · filed 2025-08-06 | $13.00M derived: sum of 3 quarters · filed 2026-02-18 | $13.00M derived: sum of 4 quarters · filed 2026-02-18 | |
| 2024-03-31 | $10.00M 10-Q · filed 2025-05-07 | $10.50M derived: sum of 2 quarters · filed 2026-02-18 | $10.50M derived: sum of 3 quarters · filed 2026-02-18 | $13.00M derived: sum of 4 quarters · filed 2026-02-18 | |
| 2023-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $500.00K derived: sum of 2 quarters · filed 2026-02-18 | $3.00M derived: sum of 3 quarters · filed 2026-02-18 | $3.00M 10-K · filed 2026-02-18 | $2.50M 10-K · filed 2024-02-21 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $2.50M derived: sum of 2 quarters · filed 2024-11-06 | $2.50M 10-Q · filed 2024-11-06 | $2.50M derived: sum of 4 quarters · filed 2025-02-19 | |
| 2023-06-30 | $2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $2.50M 10-Q · filed 2024-08-02 | $2.50M derived: sum of 3 quarters · filed 2025-02-19 | $2.50M derived: sum of 4 quarters · filed 2025-02-19 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-03 | $0.00 derived: sum of 2 quarters · filed 2025-02-19 | $0.00 derived: sum of 3 quarters · filed 2025-02-19 | $0.00 derived: sum of 4 quarters · filed 2025-02-19 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $0.00 derived: sum of 2 quarters · filed 2025-02-19 | $0.00 derived: sum of 3 quarters · filed 2025-02-19 | $30.00M 10-K · filed 2025-02-19 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $0.00 derived: sum of 2 quarters · filed 2023-11-03 | $30.00M 10-Q · filed 2023-11-03 | $30.00M derived: sum of 4 quarters · filed 2024-02-21 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $30.00M 10-Q · filed 2023-08-04 | $30.00M derived: sum of 3 quarters · filed 2024-02-21 | ||
| 2022-03-31 | $30.00M 10-Q · filed 2023-05-05 | $30.00M derived: sum of 2 quarters · filed 2024-02-21 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $0.00 10-K · filed 2024-02-21 | |||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-03 | ||||
| 2020-12-31 | -$2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $0.00 10-K · filed 2023-02-17 | |||
| 2020-09-30 | $2.27M 10-Q · filed 2020-10-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |